CRI Worldwide Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Mount Laurel NJ United States (1998)
Status: Acquired by Pharmaceutical Research Associates, Inc. (PRA) (2013) → now ICON (2021)

Organization Overview

First Clinical Trial
2007
NCT00633321
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CRI Lifetree | CRI Worldwide, LLC

Active Ingredients

Drugs in Phase 4 Trials (1)

Key: CRI Worldwide (0) Acquired (1)

propoxyphene (Darvon) (1 trial)

Drugs in Phase 3 Trials (2)

Key: CRI Worldwide (0) Acquired (2)

buprenorphine (1 trial)

naloxone (narcan) (1 trial)

Drugs in Phase 2 Trials (5)

Key: CRI Worldwide (1) Acquired (4)

azd1386 (1 trial)

conatumumab (1 trial)

fentanyl (Innovar) (1 trial)

naproxen (naprosyn) (2 trials)

ta-nic (1 trial)

Drugs in Phase 1 Trials (4)

Key: CRI Worldwide (2) Acquired (2)

lidocaine (xylocaine) (1 trial)

naltrexone (revia) (1 trial)

oxycodone (oxycontin) (1 trial)

tetracaine (pontocaine) (1 trial)

Indications

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 12